Trials / Completed
CompletedNCT06013241
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps - The BiRCh Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 288 (actual)
- Sponsor
- Insmed Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brensocatib | Film-coated tablet. |
| DRUG | Placebo | Film-coated tablet. |
| DRUG | Mometasone furoate nasal spray (MFNS) | Nasal spray suspension. |
Timeline
- Start date
- 2023-10-30
- Primary completion
- 2025-09-30
- Completion
- 2025-10-30
- First posted
- 2023-08-28
- Last updated
- 2025-11-10
Locations
100 sites across 15 countries: United States, Argentina, Australia, Belgium, Bulgaria, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Poland, Portugal, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06013241. Inclusion in this directory is not an endorsement.